The Fujimycin market in North America is well-positioned for growth, thanks to advanced medical infrastructure, large transplant volumes, and significant investment in immunosuppressive drug development. The region's concentration of top pharmaceutical players, strong clinical research ecosystem, and supportive policy and reimbursement environment make it easier for new therapies to reach...